Literature DB >> 28409388

Diethylcarbamazine attenuates the expression of pro-fibrogenic markers and hepatic stellate cells activation in carbon tetrachloride-induced liver fibrosis.

Maria Eduarda Rocha de França1,2, Sura Wanessa Santos Rocha3, Wilma Helena Oliveira3,4, Laise Aline Santos3, Anne Gabrielle Vasconcelos de Oliveira5, Karla Patrícia Sousa Barbosa6, Ana Karolina Santana Nunes3, Gabriel Barros Rodrigues3,4, Deniele Bezerra Lós3,7, Christina Alves Peixoto1.   

Abstract

BACKGROUND AND AIM: While diethylcarbamazine citrate (DEC) displays important anti-inflammatory effects in experimental models of liver injury, the mechanisms of its action remain poorly understood. The aim of the present study was to investigate the fibrolytic potential of DEC.
METHODS: Mice receive two injections of carbon tetrachloride (CCl4) per week for 8 weeks. DEC 50 mg/kg body weight was administered through drinking water during the last 12 days of liver injury.
RESULTS: The expression of hepatic stellate cells (HSCs) activation markers, including smooth muscle α-actin (α-SMA), collagen I, transforming growth factor-β 1 (TGF-β1), matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of metalloproteinase-1 (TIMP-1) was assessed. The influence of DEC on the intracellular MAPK pathways of the HSCs (JNK and p38 MAPK) was also estimated. DEC inhibited HSCs activation measured as the production of α-SMA and collagen I. In addition, it down regulated the production of TGF-β1 and TIMP-1, and concomitantly increased MMP-2 activity. Furthermore, DEC significantly inhibited the activation of the JNK and p38 MAPK signaling pathways.
CONCLUSIONS: In conclusion, DEC significantly attenuated the severity of CCl4-induced liver injury and the progression of liver fibrosis, exerting a potential fibrolytic effect in the CCl4-induced fibrosis model.

Entities:  

Keywords:  Carbon tetrachloride (CCl4); Diethylcarbamazine citrate; Liver fibrosis

Mesh:

Substances:

Year:  2017        PMID: 28409388     DOI: 10.1007/s10787-017-0329-0

Source DB:  PubMed          Journal:  Inflammopharmacology        ISSN: 0925-4692            Impact factor:   4.473


  51 in total

Review 1.  Matrix as a modulator of hepatic fibrogenesis.

Authors:  D Schuppan; M Ruehl; R Somasundaram; E G Hahn
Journal:  Semin Liver Dis       Date:  2001-08       Impact factor: 6.115

Review 2.  Mitogen-activated protein kinase pathways.

Authors:  M J Robinson; M H Cobb
Journal:  Curr Opin Cell Biol       Date:  1997-04       Impact factor: 8.382

Review 3.  Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases.

Authors:  Gary L Johnson; Razvan Lapadat
Journal:  Science       Date:  2002-12-06       Impact factor: 47.728

4.  Effect of diethylcarbamazine on chronic hepatic inflammation induced by alcohol in C57BL/6 mice.

Authors:  Sura Wanessa Santos Rocha; Bruna Santos Silva; Fabiana Oliveira dos Santos Gomes; Amanda Karolina Soares e Silva; Catarina Raposo; Karla Patrícia Sousa Barbosa; Dilênia de Oliveira Cipriano Torres; Ana Célia Oliveira dos Santos; Christina Alves Peixoto
Journal:  Eur J Pharmacol       Date:  2012-06-07       Impact factor: 4.432

Review 5.  Liver fibrosis: mechanisms of immune-mediated liver injury.

Authors:  Ruonan Xu; Zheng Zhang; Fu-Sheng Wang
Journal:  Cell Mol Immunol       Date:  2011-12-12       Impact factor: 11.530

Review 6.  Roles of TGF-beta in hepatic fibrosis.

Authors:  Axel M Gressner; Ralf Weiskirchen; Katja Breitkopf; Steven Dooley
Journal:  Front Biosci       Date:  2002-04-01

7.  Hepatoprotective effects of diethylcarbamazine in acute liver damage induced by carbon tetrachloride in rats.

Authors:  R Gonzàlez; O Ancheta; M Màrquez; S Rodriguez
Journal:  Zhongguo Yao Li Xue Bao       Date:  1994-11

Review 8.  Evolving therapies for liver fibrosis.

Authors:  Detlef Schuppan; Yong Ook Kim
Journal:  J Clin Invest       Date:  2013-05-01       Impact factor: 14.808

Review 9.  Therapy for fibrotic diseases: nearing the starting line.

Authors:  Scott L Friedman; Dean Sheppard; Jeremy S Duffield; Shelia Violette
Journal:  Sci Transl Med       Date:  2013-01-09       Impact factor: 17.956

10.  Curcumin ameliorates intrahepatic angiogenesis and capillarization of the sinusoids in carbon tetrachloride-induced rat liver fibrosis.

Authors:  Qunyan Yao; Yizheng Lin; Xi Li; Xizhong Shen; Jiyao Wang; Chuantao Tu
Journal:  Toxicol Lett       Date:  2013-07-08       Impact factor: 4.372

View more
  3 in total

1.  Human epididymis protein 4 (HE4) protects against cystic pulmonary fibrosis associated-inflammation through inhibition of NF-κB and MAPK singnaling.

Authors:  Jinli Wang; Hongyang Zhao; Fenfen Xu; Piaopiao Zhang; Yuan Zheng; Nan Jia
Journal:  Genes Genomics       Date:  2019-06-04       Impact factor: 1.839

2.  Hepatoprotection of Cinnamomum burmannii ethanolic extract against high-fat and cholesterol diet in Sprague-Dawley rats (Rattus norvegicus).

Authors:  Retno Susilowati; Abdul Malik Setiawan; Afida Fatimatuz Zahroh; Zadani Nabila Ashari; Alifatul Iffiyana; Ricky Hertanto; Muhammad Basyarudin; Isnaeni Hartiningsih; Mahrus Ismail
Journal:  Vet World       Date:  2022-04-15

3.  Diethylcarbamazine as potential treatment of COVID-19 lung fibrosis.

Authors:  Carlos Eduardo Medina-De la Garza; Armando Salvador Flores-Torres; Marisela García-Hernández; María de Los Ángeles Castro-Corona
Journal:  Med Hypotheses       Date:  2022-01-25       Impact factor: 1.538

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.